Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Unknown 4Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 3Advanced Solid Cancer 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Interventional × SH-1028 × Clear all
NCT04239833 2020-01-27

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 3 Unknown
240 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03823807 2019-02-01

A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2 Unknown
300 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03618043 2019-01-29

Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 1 Unknown
14 enrolled

Advanced Solid Cancer

NCT03603262 2019-01-28

Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 1 Unknown
85 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡